Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
University of California, San Francisco · UCSF Helen Diller Family Comprehensive Cancer Center · +27 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,345
total citations
- FWCI
- 115.73
- Percentile
- 100%
- References
- 26
Citations per year
Authors
25- CJCharles J. RyanCorresponding
University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center
- MRMatthew R. Smith
Harvard University, Massachusetts General Hospital
- KFKarim Fizazi
Université Paris-Sud, Institut Gustave Roussy
- FSFred Saad
Université de Montréal
- PFPeter F.A. Mulders
Radboud University Nijmegen, Radboud University Medical Center
Topics & keywords
Topics
Keywords
- Abiraterone acetate
- Prednisone
- Medicine
- Prostate cancer
- Placebo
- Internal medicine
- Oncology
- Castration
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.